JOEL AMBROSIO: Open Payments
NPI 1154628105 · OAKLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,254 in 43 payments from 12 companies in 2025. Trend: 2023 $806 · 2024 $1,723 · 2025 $1,254
Food & beverage: $1,254
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 11 | $448 |
| Madrigal Pharmaceuticals | 6 | $196 |
| ABBVIE INC. | 8 | $187 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $120 |
| QOL Medical, LLC | 3 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $71 |
| Janssen Biotech, Inc. | 2 | $46 |
| Gilead Sciences, Inc. | 1 | $34 |
| Organon LLC | 1 | $26 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
Products named: OMVOH, REZDIFFRA, RINVOQ, XIFAXAN, Sucraid, TREMFYA, EOHILIA, ENTYVIO.
Industry payments across CA — which companies pay providers there.
